London, UK-based Mereo BioPharma’s experimental drug targeting brittle bone disease has been designated PRIME status by the European Medicines Agency (EMA).
The National Institute for Health Research Efficacy and Mechanism Evaluation (EME) Programme is funding a new £1.5 million trial testing a combination of therapies to prevent rapture in patients with brittle bone disease.